However, CRC patients bearing WT KRAS respond to cetuximab only to some degrees.40 Thus, a more detailed study of deregulated EGF pathway in CRC needs to be further characterized to help guide treatment and improve clinical care. The gene discussed is EGF; the disease is colorectal carcinoma.